Close Menu

NEW YORK (GenomeWeb) – Genome editing company Precision BioSciences today priced the initial public offering of its common stock, and is aiming to raise $126.4 million in gross proceeds from the sale.

The company priced 7.9 million shares of common stock at $16 per share, and is granting the underwriters a 30-day option to purchase approximately 1.2 million additional shares at the IPO price. The shares began trading on the Nasdaq Global Select Market under the ticker symbol DTIL today, and the offering is expected to close on April 1.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.

Resistance to ash dieback disease among some UK ash trees appears polygenic, the Independent reports.

In Nucleic Acids Research this week: sequencing strategy for flash-frozen brain tissue bank samples, new version of ChlamDB, and more.

A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.